Literature DB >> 24567196

Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.

Katherine Drews-Elger1, Joeli A Brinkman, Philip Miller, Sanket H Shah, J Chuck Harrell, Thiago G da Silva, Zheng Ao, Amy Schlater, Diana J Azzam, Kathleen Diehl, Dafydd Thomas, Joyce M Slingerland, Charles M Perou, Marc E Lippman, Dorraya El-Ashry.   

Abstract

Our goal was to establish primary cultures from dissociation of breast tumors in order to provide cellular models that may better recapitulate breast cancer pathogenesis and the metastatic process. Here, we report the characterization of six cellular models derived from the dissociation of primary breast tumor specimens, referred to as "dissociated tumor (DT) cells." In vitro, DT cells were characterized by proliferation assays, colony formation assays, protein, and gene expression profiling, including PAM50 predictor analysis. In vivo, tumorigenic and metastatic potential of DT cultures was assessed in NOD/SCID and NSG mice. These cellular models differ from recently developed patient-derived xenograft models in that they can be used for both in vitro and in vivo studies. PAM50 predictor analysis showed DT cultures similar to their paired primary tumor and as belonging to the basal and Her2-enriched subtypes. In vivo, three DT cultures are tumorigenic in NOD/SCID and NSG mice, and one of these is metastatic to lymph nodes and lung after orthotopic inoculation into the mammary fat pad, without excision of the primary tumor. Three DT cultures comprised of cancer-associated fibroblasts (CAFs) were isolated from luminal A, Her2-enriched, and basal primary tumors. Among the DT cells are those that are tumorigenic and metastatic in immunosuppressed mice, offering novel cellular models of ER-negative breast cancer subtypes. A group of CAFs provide tumor subtype-specific components of the tumor microenvironment (TME). Altogether, these DT cultures provide closer-to-primary cellular models for the study of breast cancer pathogenesis, metastasis, and TME.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24567196     DOI: 10.1007/s10549-014-2887-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.

Authors:  D Zhao; C Pan; J Sun; C Gilbert; K Drews-Elger; D J Azzam; M Picon-Ruiz; M Kim; W Ullmer; D El-Ashry; C J Creighton; J M Slingerland
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

2.  Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype.

Authors:  Sanket H Shah; Philip Miller; Marta Garcia-Contreras; Zheng Ao; Leah Machlin; Emilio Issa; Dorraya El-Ashry
Journal:  Cancer Biol Ther       Date:  2015-07-17       Impact factor: 4.742

3.  Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Authors:  T Kwak; K Drews-Elger; A Ergonul; P C Miller; A Braley; G H Hwang; D Zhao; A Besser; Y Yamamoto; H Yamamoto; D El-Ashry; J M Slingerland; M E Lippman; B I Hudson
Journal:  Oncogene       Date:  2016-09-26       Impact factor: 9.867

4.  Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.

Authors:  Yuqi Jing; Valery Chavez; Yuguang Ban; Nicolas Acquavella; Doraya El-Ashry; Alexey Pronin; Xi Chen; Jaime R Merchan
Journal:  Mol Cancer Res       Date:  2017-07-05       Impact factor: 5.852

5.  Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis.

Authors:  Utsav Sharma; Kelsie Medina-Saenz; Philip C Miller; Benjamin Troness; Angela Spartz; Ana Sandoval-Leon; Deanna N Parke; Tiffany N Seagroves; Marc E Lippman; Dorraya El-Ashry
Journal:  Breast Cancer Res Treat       Date:  2021-07-03       Impact factor: 4.872

6.  The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.

Authors:  Zhenbo Tu; Johannes Schmoellerl; Odette Mariani; Yurong Zheng; Yi Hu; Anne Vincent-Salomon; Antoine E Karnoub
Journal:  NPJ Breast Cancer       Date:  2021-05-31

7.  Modelling circulating tumour cells for personalised survival prediction in metastatic breast cancer.

Authors:  Gianluca Ascolani; Annalisa Occhipinti; Pietro Liò
Journal:  PLoS Comput Biol       Date:  2015-05-15       Impact factor: 4.475

8.  Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression.

Authors:  E T Goka; M E Lippman
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

9.  In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.

Authors:  Yuqi Jing; Valery Chavez; Natasha Khatwani; Yuguang Ban; Andrea P Espejo; Xi Chen; Jaime R Merchan
Journal:  Cancer Gene Ther       Date:  2020-03-31       Impact factor: 5.987

10.  Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.

Authors:  Shunchao Yan; Parama Dey; Yvonne Ziegler; Xin Jiao; Sung Hoon Kim; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Breast Cancer Res Treat       Date:  2020-10-01       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.